Publicaciones en colaboración con investigadores/as de University of Oxford (11)

2019

  1. Cerebral oxidative metabolism mapping in four genetic mouse models of anxiety and mood disorders

    Behavioural Brain Research, Vol. 356, pp. 435-443

2015

  1. A multicentre comparison of quantitative 90Y PET/CT for dosimetric purposes after radioembolization with resin microspheres: The QUEST Phantom Study

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 42, Núm. 8, pp. 1202-1222

2011

  1. Shared changes in gene expression in frontal cortex of four genetically modified mouse models of depression

    European Neuropsychopharmacology, Vol. 21, Núm. 1, pp. 3-10

2010

  1. Regulation of markers of synaptic function in mouse models of depression: Chronic mild stress and decreased expression of VGLUT1

    Journal of Neurochemistry, Vol. 114, Núm. 5, pp. 1302-1314

  2. Sustained stress-induced changes in mice as a model for chronic depression

    Psychopharmacology, Vol. 210, Núm. 3, pp. 393-406

2007

  1. Enhanced anxiety, depressive-like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1)

    European Journal of Neuroscience, Vol. 25, Núm. 1, pp. 281-290

2005

  1. Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment

    Journal of Neurochemistry, Vol. 94, Núm. 4, pp. 875-883

2004

  1. Glutamate receptor activation is involved in 5-HT2 agonist-induced Arc gene expression in the rat cortex

    Neuropharmacology, Vol. 46, Núm. 3, pp. 331-339

2003

  1. Antidepressant drug treatment induces Arc gene expression in the rat brain

    Neuroscience, Vol. 121, Núm. 4, pp. 975-982

  2. Effect of different 5-HT1A receptor antagonists in combination with paroxetine on expression of the immediate-early gene Arc in rat brain

    Neuropharmacology, Vol. 44, Núm. 7, pp. 893-902

  3. Use of Arc expression as a molecular marker of increased postsynaptic 5-HT function after SSRI/5-HT1A receptor antagonist co-administration

    Journal of Neurochemistry, Vol. 85, Núm. 6, pp. 1480-1487